ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

DuBois Succeeds Hait As AACR President, Jacks Is President-Elect.

April 18, 2008

Radiation Table Recommendations Completed

July 22, 1983

In Brief: Heavy Smokers More Resistant To Quitting,

March 10, 1995

Iressa Just As Effective As Chemotherapy For Second-Line Therapy, Study Finds

November 28, 2008

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

ASCO/AUA Suggest 5-ARIs To Cut Prostate Cancer Risk

February 27, 2009